Overview of the drug development for angina pectoris
Angina pectoris occurs when the flow of blood through the coronary veins is inadequate. This chronic condition is different from a heart attack as the reduction in blood flow to the heart muscle is only temporary while not damaging the heart muscle. The condition is often classified as stable angina, unstable angina, and variant angina. Common symptoms of the condition include persistent moderate of severe indigestion, shortness of breath, tiredness, nausea, sweating, and dizziness. Various treatment options for angina pectoris include the Beta-blockers, antiplatelets, angioplasty, coronary artery bypass surgery and other treatments. According to the American Heart Association (AHA), about 15.5 million people aging above 20 had coronary heart disease in 2016. With continuous aging, the incidences of angina pectoris are likely to increase considerably in the forthcoming years.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for the treatment of angina. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered in this pipeline analysis report
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of angina. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also includes information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- XyloCor Therapeutics
- Sanofi
- Juventas Therapeutics
- Hemostemix
Therapeutic assessment of the drug development for angina pectoris by route of administration
- Oral
- IV
- Intramuscular
The IV route of administration (ROA) involves the application of the drug intravenously, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development for angina pectoris by therapy
- Monotherapy
- Combination therapy
All molecules that are currently in the drug development pipeline for the treatment of angina pectoris are being developed as monotherapy drugs.
Key questions answered in the report include
- What are the drug molecules in the various development stages for angina pectoris?
- What are the companies that are currently involved in the drug development for angina pectoris?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.